Cargando…

Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions

Background: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions...

Descripción completa

Detalles Bibliográficos
Autores principales: Canonica, Giorgio Walter, Arp, Jan, Keegstra, Johan René, Chrystyn, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601554/
https://www.ncbi.nlm.nih.gov/pubmed/26352860
http://dx.doi.org/10.1089/jamp.2015.1216
_version_ 1782394567095484416
author Canonica, Giorgio Walter
Arp, Jan
Keegstra, Johan René
Chrystyn, Henry
author_facet Canonica, Giorgio Walter
Arp, Jan
Keegstra, Johan René
Chrystyn, Henry
author_sort Canonica, Giorgio Walter
collection PubMed
description Background: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to patients with asthma or COPD. Methods: Dose-delivery studies were performed using low-, middle-, and high-strength DuoResp Spiromax. Dose consistency was assessed over inhaler life. Total emitted doses (TEDs) were measured at various flow rates, after exposure to high and low temperature or humidity, at different inhaler orientations, and after dropping the inhaler. The criterion for evaluating dose uniformity was whether mean TEDs were within the product specification limits. In separate studies, flow rates were measured after training, using the patient information leaflets, and again after enhanced training as part of a randomized, open-label, cross-over study. Results: Mean values for both budesonide and formoterol were within 85%–115% of the label claim for each strength of DuoResp Spiromax for initial dose uniformity and for the other investigated conditions (temperature, humidity, orientation, dropping, knocking), with the exception of approximately an 80% increase in first dose after dropping the inhaler (subsequent doses not affected). In the flow rate patient study, two patients' inhalations with Spiromax and six with Turbuhaler were <30 L/min. The majority of asthma patients [91% (Spiromax) versus 82% (Turbuhaler)] achieved the preferred flow rate of >60 L/min. Conclusions: DuoResp Spiromax consistently meets dose uniformity criteria, under controlled laboratory conditions and with variations intended to mimic real-world use. Following enhanced training, all patients in the flow study were able to achieve the minimal inspiratory flow rate of >30 L/min, which is required for effective treatment.
format Online
Article
Text
id pubmed-4601554
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-46015542015-10-20 Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions Canonica, Giorgio Walter Arp, Jan Keegstra, Johan René Chrystyn, Henry J Aerosol Med Pulm Drug Deliv Original Research Background: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to patients with asthma or COPD. Methods: Dose-delivery studies were performed using low-, middle-, and high-strength DuoResp Spiromax. Dose consistency was assessed over inhaler life. Total emitted doses (TEDs) were measured at various flow rates, after exposure to high and low temperature or humidity, at different inhaler orientations, and after dropping the inhaler. The criterion for evaluating dose uniformity was whether mean TEDs were within the product specification limits. In separate studies, flow rates were measured after training, using the patient information leaflets, and again after enhanced training as part of a randomized, open-label, cross-over study. Results: Mean values for both budesonide and formoterol were within 85%–115% of the label claim for each strength of DuoResp Spiromax for initial dose uniformity and for the other investigated conditions (temperature, humidity, orientation, dropping, knocking), with the exception of approximately an 80% increase in first dose after dropping the inhaler (subsequent doses not affected). In the flow rate patient study, two patients' inhalations with Spiromax and six with Turbuhaler were <30 L/min. The majority of asthma patients [91% (Spiromax) versus 82% (Turbuhaler)] achieved the preferred flow rate of >60 L/min. Conclusions: DuoResp Spiromax consistently meets dose uniformity criteria, under controlled laboratory conditions and with variations intended to mimic real-world use. Following enhanced training, all patients in the flow study were able to achieve the minimal inspiratory flow rate of >30 L/min, which is required for effective treatment. Mary Ann Liebert, Inc. 2015-10-01 /pmc/articles/PMC4601554/ /pubmed/26352860 http://dx.doi.org/10.1089/jamp.2015.1216 Text en © The Author(s) 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Canonica, Giorgio Walter
Arp, Jan
Keegstra, Johan René
Chrystyn, Henry
Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
title Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
title_full Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
title_fullStr Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
title_full_unstemmed Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
title_short Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
title_sort spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601554/
https://www.ncbi.nlm.nih.gov/pubmed/26352860
http://dx.doi.org/10.1089/jamp.2015.1216
work_keys_str_mv AT canonicagiorgiowalter spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions
AT arpjan spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions
AT keegstrajohanrene spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions
AT chrystynhenry spiromaxanewdrypowderinhalerdoseconsistencyundersimulatedrealworldconditions